VedaBio Expands CRISPR-Based Molecular Detection Platform

VedaBio announced a non-exclusive license agreement with Mammoth Biosciences Inc. for the use of select CRISPR-based technologies in diagnostic applications.

The agreement provides VedaBio with access to foundational CRISPR intellectual property, enabling the company to accelerate development of purpose-built diagnostic solutions. This alliance reinforces VedaBio’s commitment to building a next-generation platform designed for speed and accuracy, with an initial focus on decentralized healthcare settings.

“We’re thrilled to work with the Mammoth team to help bring the full promise of CRISPR-based diagnostics to market,” VedaBio President/CEO Frederic Sweeney, Ph.D., said. “This initiative expands the avenues for our proprietary platform and allows us to develop highly targeted, amplification-free molecular tests designed for real-world clinical needs.”

CRISPR-based detection allows for highly specific molecular recognition. When integrated with VedaBio’s platform, it opens the door to rapid, accurate diagnostics that can be deployed in urgent care, outpatient clinics, and other decentralized settings, without sacrificing sensitivity or specificity.

With this partnership, VedaBio is positioned to lead the next wave of CRISPR-powered diagnostics, delivering solutions that are faster, more cost-effective, and better aligned with the realities of today’s healthcare landscape, according to company bigwigs.

“Mammoth’s vision for diagnostics is to enable new solutions that have high impact on patient care.  The combination of Mammoth’s deep CRISPR intellectual property with VedaBio’s unique approach and product vision is an opportunity to deliver on the potential of CRISPR-based diagnostics,” Mammoth Biosciences Co-Founder/Chief Technology Officer Janice Chen, Ph.D., stated.

VedaBio harnesses cutting-edge CRISPR technology to deliver rapid, accurate, accessible diagnostics.

Mammoth Biosciences is a biotechnology company that leverages its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact systems are designed to be more specific and enable in vivo gene editing in difficult-to-reach tissues using both nuclease applications and new editing modalities beyond double stranded breaks including base editing, reverse transcriptase editing, and epigenetic editing. The company is building out its wholly owned pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with pharmaceutical and biotechnology companies to broaden the reach of its proprietary technology platform.